Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | LPL | P06858 | 5/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422542 | 0.94 | P2RX7 (0.89) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL16020506 | 0.92 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL16189840 | 0.92 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL4421394 | 0.92 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL16189763 | 0.92 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL17470588 | 0.92 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL2313496 | 0.92 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL19383987 | 0.92 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL2313492 | 0.92 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL30965858 | 0.89 | P2RX7 (0.80) | P2RX7MAPK1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 819 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116917280-B | Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4294804-B1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720067-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | Recursion Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12595270-B2 | Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| EP-3562828-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4041732-B1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | ZHEJIANG METON PHARMACEUTICAL CO LTD (CN) | 2026-03-18 | — | — | EP | disclosed |
| EP-4702017-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2026-03-04 | — | — | EP | disclosed |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4688754-A1 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035385-A1 | BENZO NITROGEN-CONTAINING HETEROAROMATIC RING DERIVATIVE AND USE THEREOF IN MEDICINE | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2026-02-05 | — | — | US | disclosed |
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| WO-2010146173-A1 | QUINAZOLINE DERIVATIVES AS HISTAMINE H4-RECEPT0R INHIBITORS FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010135560-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010126960-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-1703909-B1 | 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7462617-B2 | Substituted acylpiperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | P2RX7 323/4885MAPK1 3790/4885LPL 2966/4885 |
| US-20260035385-A1 | BENZO NITROGEN-CONTAINING HETEROAROMATIC RING DERIVATIVE AND USE THEREOF IN MEDICINE | CYP2F1, CFH, CYP4F11 | P2RX7 3180/4885MAPK1 2585/4885LPL 1990/4885 |
| US-20050059668-A1 | Substituted acylpiperazine derivatives | AGPAT5, ACHE, GRIK5 | P2RX7 509/4885MAPK1 2760/4885LPL 247/4885 |
| US-12595270-B2 | Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine | CYP2F1, CYP4F11, CFH | P2RX7 3187/4885MAPK1 2642/4885LPL 1933/4885 |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPK13, MAPKAPK5 | P2RX7 1805/4885MAPK1 9/4885LPL 4307/4885 |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | P2RX7 3523/4885MAPK1 1348/4885LPL 2108/4885 |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | P2RX7 1898/4885MAPK1 12/4885LPL 4622/4885 |
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | P2RX7 4700/4885MAPK1 1138/4885LPL 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.